USC–UCLA Drug-Related Liver Injury Center
USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center
This program enrolls people who have had liver injury from medicines, supplements, or cancer immunotherapy so doctors can collect medical information and samples to improve care.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-11170034 on NIH RePORTER |
What this research studies
If you join, you would be seen at USC or UCLA and your doctors would document your medical history, medications, and test results over time. The team collects blood and other samples for future lab studies and stores data in the DILIN network database. The center focuses on enrolling people from underrepresented communities in Los Angeles and cases linked to herbal or dietary supplements and checkpoint inhibitor immunotherapy. Researchers will also study how immune reactions and cell death contribute to liver injury from certain cancer drugs.
Who could benefit from this research
Good fit: Ideal candidates are people who recently developed unexplained liver injury suspected to be caused by prescription drugs, over-the-counter medicines, herbal or dietary supplements, or cancer immunotherapy.
Not a fit: People whose liver disease is clearly due to non-drug causes (for example untreated viral hepatitis, alcohol-related liver disease, or known genetic liver disorders) may not receive direct benefit from this center.
Why it matters
Potential benefit: If successful, this work could help clinicians identify causes of drug-related liver injury sooner, guide safer medication choices, and point to better treatments or prevention strategies.
How similar studies have performed: The Drug-Induced Liver Injury Network (DILIN) is an established program that has successfully enrolled patients and produced important findings on causes and outcomes of DILI, and this center continues that work.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Dara, Lily — University of Southern California
- Study coordinator: Dara, Lily
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.